Selected Articles from This Issue

Abstract

Highlights| June 01 2023 Selected Articles from This Issue Author & Article Information Online ISSN: 1538-8514 Print ISSN: 1535-7163 ©2023 American Association for Cancer Research2023American Association for Cancer Research Mol Cancer Ther (2023) 22 (6): 691. https://doi.org/10.1158/1535-7163.MCT-22-6-HI Related Content A commentary has been published: Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers A commentary has been published: Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma A commentary has been published: Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors View more A commentary has been published: Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record June 1 2023 Citation Selected Articles from This Issue. Mol Cancer Ther 1 June 2023; 22 (6): 691. https://doi.org/10.1158/1535-7163.MCT-22-6-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Hepatocellular carcinoma (HCC) remains a global medical burden with a rising incidence and has a dismal prognosis. Cancer cells, including HCC cells, exhibit an oncogenetically driven addiction to the neutral amino acid glutamine. Here, Wei et al. report that drug candidate RX108, a novel small-molecule inhibitor of Na+/K+-ATPase, exerts potent antitumor activities and significantly decreases cell energy metabolism in HCC cells and xenograft model. Intriguingly, the antiproliferative effect of RX108 is dependent on glutamine transport and mediated by ASCT2 (SLC1A5), a sodium-dependent transporter for glutamine. These findings reveal a novel approach to target glutamine metabolism through inhibiting Na+/K+-ATPase. Radiation therapy has historically been used for localized cancer treatment with curative intent. However, recent advances in immunotherapy and its integration into standard cancer care have brought attention to the intriguing 'abscopal effect.' Nelson and colleagues shed light on this once poorly understood phenomenon,... You do not currently have access to this content.